

India

Overweight (no change)

Highlighted Companies

Cyient DLM Ltd

ADD, TP Rs1049, Rs610 close

Cyient DLM's revenue is expected to continue its strong export-driven growth. Europe's increased defence spending due to the Russia-Ukraine war and NATO's 2% GDP defence spending target could be a medium-term trigger for growth, particularly for Cyient DLM's clients. This could lead to a significant order inflow for Cyient DLM, resulting in order book growth.

Dixon Technologies

ADD, TP Rs9010, Rs8851 close

Dixon Technologies' business model is highly scalable and profitable, with high fungibility in its product line. Technological upgradation in the 5G infrastructure is poised to open new possibilities for electronic devices, especially in the mobility & communication segments.

PG Electroplast

REDUCE, TP Rs1755, Rs2467 close

RAC sales are expected to drive PGEL's growth in FY25F while its coolers and washing machines are slow to ramp up. Going ahead, PLI incentives will be in the range of Rs0.55-0.60bn in FY25F and FY26F.

Summary Valuation Metrics

| P/E (x) | Mar24-A | Mar25-F | Mar26-F |
|--------------------|---------|---------|---------|
| Cyient DLM Ltd | 79.18 | 40.11 | 25.97 |
| Dixon Technologies | 139.99 | 88.17 | 63.86 |
| PG Electroplast | 46.81 | 34.69 | 32.39 |

| P/BV (x) | Mar24-A | Mar25-F | Mar26-F |
|--------------------|---------|---------|---------|
| Cyient DLM Ltd | 5.32 | 4.7 | 3.98 |
| Dixon Technologies | 31.23 | 23.32 | 17.22 |
| PG Electroplast | 6.18 | 5.23 | 4.47 |

| Dividend Yield | Mar24-A | Mar25-F | Mar26-F |
|--------------------|---------|---------|---------|
| Cyient DLM Ltd | 0% | 0% | 0% |
| Dixon Technologies | 0.03% | 0.05% | 0.05% |
| PG Electroplast | 0% | 0% | 0% |

Research Analyst(s)



Arafat SAIYED

T (91) 22 4161 1542

E arafat.saiyed@incredcapital.com

Vipraw SRIVASTAVA

T (91) 22 4161 1565

E vipraw.srivastava@incredresearch.com

Anirvan DIVAKERA

T (91) 02241611548

E anirvan.divakera@incredresearch.com

EMS

4QFY24 results review

- The EMS universe reported sales/EBITDA/PAT YoY growth of 31%/17%/22%, respectively, in 4Q led by strong revenue growth with a lower margin for Dixon.
- Management commentary was positive regarding the government incentives, including white goods, IT PLI scheme & the Semiconductor Mission.
- We expect EMS companies to report a healthy growth over the next few years. Our top picks include Cyient DLM and Dixon while our top REDUCE is PGEL.

EMS space likely to see further expansion

The electronic manufacturing services or EMS coverage universe reported healthy sales/EBITDA/PAT YoY growth of 31%/17%/22%, respectively, in 4QFY24 led by strong revenue growth with a lower margin of Dixon Technologies. Keynes Technology reported the highest revenue growth at ~75% YoY followed by Syrma SGS Technology at 67% and Dixon Technologies at 64%. The margin of our coverage universe declined by 80bp YoY to 6.7% in 4QFY24, mainly due to the change in product mix. Most companies reported lower margin, with the highest decline seen in Avalon Technologies (down 719bp YoY), IKIO Lighting (down 412 bp YoY), and Syrma SGS Technology (down 222 bp YoY). On the profitability front, strong PAT growth was seen in Elin Electronics (119% YoY), Keynes Technology (97% YoY) and Cyient DLM (81% YoY).

Management commentary

Management commentary was positive from the companies considering the government incentives, including the white goods and IT PLI schemes and the National Semiconductor Mission. However, the white goods PLI scheme had unintended consequences for room air-conditioner or RAC manufacturers, as major brands are establishing their own manufacturing facilities. **Dixon Technologies** posted a healthy performance, and the company achieved a significant milestone by producing 15bn smartphones and 38bn feature phones during the year. Management remains positive, and the company is looking at the opportunity in the PCB assembly EMS space, expecting turnover next year. For **Cyient DLM**, management expects a 30% revenue CAGR over a three-year period. It expects 25% RoCE in the next five years.

Outlook & valuation

We expect EMS companies to report a healthy growth over the next few years led by 1) government initiatives like the PLI scheme, 'Make in India' program, etc., 2) the China + 1 strategy, as many global players look towards shifting from China, and 3) higher electronic content across major end-user sectors like automobile (including EVs), consumer durables, industrials and defence. **Top Picks:** We like **Cyient DLM**, which offers electronics solutions for mission-critical applications with high entry barriers, **Dixon Technologies**, which is highly scalable and profitable, with high fungibility in its products line. Our **top REDUCE-rated stock** includes **PG Electroplast**, as a major portion of its growth is likely to come from RAC, as its coolers and washing machines are not ramping up fast enough.

Figure 1: Summary of our coverage universe

| BBG | Rating | Mcap (Rs m) | CMP (Rs) | TP (Rs) | Target P/E (Rs) | Share (m) |
|-------------|--------|-------------|----------|---------|-----------------|-----------|
| DIXON IN | ADD | 5,27,101 | 8,851 | 9,010 | 65 | 60 |
| AMBER IN | HOLD | 1,19,138 | 3,536 | 4,200 | 35 | 34 |
| PGEL IN | REDUCE | 64,195 | 2,467 | 1,755 | 22 | 26 |
| KAYNES IN | HOLD | 1,81,323 | 2,837 | 3,286 | 55 | 64 |
| SYRMA IN | ADD | 78,896 | 446 | 437 | 28 | 177 |
| AVALON IN | HOLD | 30,981 | 471 | 510 | 35 | 66 |
| CYIENTDL IN | ADD | 48,357 | 610 | 1,048 | 45 | 79 |
| IKIO IN | REDUCE | 19,092 | 247 | 260 | 19 (EV/EBITDA) | 77 |
| ELIN IN | ADD | 7,510 | 151 | 198 | 15 | 50 |

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 2: Quarterly results review

| | Revenue (Rs m) | | | | | EBITDA (Rs m) | | | | | PAT (Rs m) | | | | |
|------------------|-----------------|---------------|--------------|---------------|--------------|---------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| | Mar-24 | Mar-23 | YoY (%) | Dec-23 | QoQ (%) | Mar-24 | Mar-23 | YoY (%) | Dec-23 | QoQ (%) | Mar-24 | Mar-23 | YoY (%) | Dec-23 | QoQ (%) |
| Dixon | 50,166 | 30,655 | 63.7% | 48,184 | 4.1% | 1,825 | 1,563 | 16.7% | 1,846 | -1.1% | 973 | 790 | 23.1% | 980 | -0.7% |
| Amber | 28,054 | 30,026 | -6.6% | 12,948 | 116.7% | 2,218 | 2,035 | 9.0% | 785 | 182.6% | 990 | 1,040 | -4.8% | -5 | NA |
| PG | 10,766 | 8,282 | 30.0% | 5,319 | 102.4% | 1,165 | 757 | 53.8% | 420 | 177.5% | 716 | 402 | 78.1% | 192 | 273.2% |
| Kaynes | 6,373 | 3,646 | 74.8% | 5,093 | 25.1% | 952 | 594 | 60.5% | 699 | 36.3% | 813 | 413 | 96.8% | 452 | 79.8% |
| Syrma | 11,341 | 6,795 | 66.9% | 7,067 | 60.5% | 737 | 592 | 24.4% | 388 | 89.9% | 452 | 423 | 6.9% | 203 | 122.9% |
| Avalon | 2,168 | 2,718 | -20.2% | 2,143 | 1.2% | 172 | 411 | -58.2% | 165 | 3.9% | 71 | 227 | -68.9% | 66 | 7.4% |
| Cyient DLM | 3,618 | 2,774 | 30.5% | 3,210 | 12.7% | 380 | 319 | 19.2% | 293 | 29.7% | 227 | 126 | 80.7% | 183 | 24.2% |
| IKIO | 948 | 1,180 | -19.7% | 1,168 | -18.8% | 170 | 260 | -34.7% | 262 | -35.3% | 95 | 140 | -32.0% | 189 | -49.5% |
| Elin | 2,778 | 2,687 | 3.4% | 2,367 | 17.4% | 124 | 89 | 39.9% | 85 | 46.1% | 35 | 16 | 118.6% | 26 | 33.9% |
| Aggregate | 1,16,213 | 88,763 | 30.9% | 87,499 | 32.8% | 7,742 | 6,619 | 17.0% | 4,943 | 56.6% | 4,372 | 3,577 | 22.2% | 2,286 | 91.2% |

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 3: Full-year (FY24) results review

| | Revenue (Rs m) | | | EBITDA (Rs m) | | | PAT (Rs m) | | |
|------------------|-----------------|-----------------|--------------|---------------|---------------|--------------|---------------|--------------|--------------|
| | FY24 | FY23 | YoY (%) | FY24 | FY23 | YoY (%) | FY24 | FY23 | YoY (%) |
| Dixon | 1,76,911 | 1,21,920 | 45.1% | 6,978 | 5,127 | 36.1% | 3,729 | 2,534 | 47.1% |
| Amber | 67,292 | 69,271 | -2.9% | 4,918 | 4,179 | 17.7% | 1,373 | 1,572 | -12.7% |
| PG | 27,465 | 21,491 | 27.8% | 2,618 | 1,652 | 58.4% | 1,370 | 774 | 76.9% |
| Kaynes | 18,046 | 11,261 | 60.3% | 2,542 | 1,683 | 51.0% | 1,834 | 952 | 92.7% |
| Syrma | 31,538 | 20,484 | 54.0% | 1,984 | 1,878 | 5.7% | 1,257 | 1,231 | 2.1% |
| Avalon | 8,672 | 9,446 | -8.2% | 626 | 1,127 | -44.5% | 280 | 524 | -46.6% |
| Cyient DLM | 11,918 | 8,320 | 43.2% | 1,109 | 878 | 26.4% | 611 | 317 | 92.5% |
| IKIO | 4,379 | 3,588 | 22.0% | 926 | 775 | 19.6% | 605 | 500 | 20.9% |
| Elin | 10,417 | 10,754 | -3.1% | 405 | 646 | -37.2% | 139 | 265 | -47.7% |
| Aggregate | 3,56,638 | 2,76,536 | 29.0% | 22,106 | 17,945 | 23.2% | 11,196 | 8,671 | 29.1% |

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 4: Quarterly and full-year margin comparison

| | Qtr EBITDA Margin (%) | | | | FY EBITDA Margin (%) | | | |
|------------------|-----------------------|-------------|------------|-------------|----------------------|-------------|-------------|------------|
| | Mar-24 | Mar-23 | YoY (bp) | Dec-23 | QoQ (bp) | FY24 | FY23 | YoY (bp) |
| Dixon | 3.6% | 5.1% | -146 | 3.8% | -19 | 3.9% | 4.2% | -26 |
| Amber | 7.9% | 6.8% | 113 | 6.1% | 184 | 7.3% | 6.0% | 128 |
| PG | 10.8% | 9.1% | 167 | 7.9% | 293 | 9.5% | 7.7% | 184 |
| Kaynes | 14.9% | 16.3% | -134 | 13.7% | 122 | 14.1% | 14.9% | -86 |
| Syrma | 6.5% | 8.7% | -222 | 5.5% | 101 | 6.3% | 9.2% | -288 |
| Avalon | 7.9% | 15.1% | -719 | 7.7% | 21 | 7.2% | 11.9% | -472 |
| Cyient DLM | 10.5% | 11.5% | -99 | 9.1% | 137 | 9.3% | 10.6% | -124 |
| IKIO | 17.9% | 22.0% | -412 | 22.4% | -456 | 21.2% | 21.6% | -44 |
| Elin | 4.5% | 3.3% | 117 | 3.6% | 88 | 3.9% | 6.0% | -211 |
| Aggregate | 6.7% | 7.5% | -80 | 5.6% | 101 | 6.2% | 6.5% | -29 |

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 5: Quarterly aggregate performance

| Aggregate | Mar-24 | Mar-23 | YoY (%) | Dec-23 | QoQ (%) |
|-------------------|----------|--------|---------|--------|---------|
| Revenue (Rs m) | 1,19,968 | 88,763 | 35.2% | 87,499 | 37.1% |
| EBITDA (Rs m) | 7,914 | 6,619 | 19.6% | 4,943 | 60.1% |
| EBITDA margin (%) | 6.6% | 7.5% | -86 bps | 5.6% | 95 bps |
| PAT (Rs m) | 4,292 | 3,577 | 20.0% | 2,286 | 87.7% |

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 6: Quarterly PCBA players' performance

| EMS (PCBA) | Mar-24 | Mar-23 | YoY (%) | Dec-23 | QoQ (%) |
|-------------------|--------|--------|---------|--------|---------|
| Revenue (Rs m) | 20,772 | 15,933 | 30.4% | 17,513 | 18.6% |
| EBITDA (Rs m) | 2,031 | 1,916 | 6.0% | 1,546 | 31.4% |
| EBITDA margin (%) | 9.8% | 12.0% | -225 bp | 8.8% | 95 bp |
| PAT (Rs m) | 1,294 | 1,189 | 8.8% | 904 | 43.2% |

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 7: Quarterly consumer EMS players' performance

| EMS (Consumer) | Mar-24 | Mar-23 | YoY (%) | Dec-23 | QoQ (%) |
|-------------------|--------|--------|---------|--------|---------|
| Revenue (Rs m) | 99,195 | 72,830 | 36.2% | 69,986 | 41.7% |
| EBITDA (Rs m) | 5,882 | 4,704 | 25.1% | 3,397 | 73.2% |
| EBITDA margin (%) | 5.9% | 6.5% | -53 bp | 4.9% | 108 bp |
| PAT (Rs m) | 2,998 | 2,388 | 25.5% | 1,383 | 116.9% |


SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 8: 4QFY24 revenue, EBITDA, PAT variation and revision

| Company | Revenue | EBITDA | PAT | Revenue Miss/Beat | EBITDA Miss/Beat | PAT Miss/Beat | Revenue Change (%) | | EBITDA Change (%) | | EPS Change (%) | |
|------------|---------|--------|-----|-------------------|------------------|---------------|--------------------|--------|-------------------|--------|----------------|--------|
| | | | | | | | FY25F | FY26F | FY25F | FY26F | FY25F | FY26F |
| Dixon | 50,166 | 1,825 | 973 | -7.1% | -21.6% | -20.9% | 15.7% | 20.5% | 4.7% | 9.1% | 2.7% | 9.1% |
| Amber | 28,054 | 2,218 | 990 | -15.6% | -1.0% | -18.3% | -6.9% | -6.6% | 6.2% | 9.1% | 5.0% | 10.2% |
| PG | 10,766 | 1,165 | 716 | -5.4% | 24.8% | 30.2% | -3.1% | -7.8% | 37.9% | 25.0% | 57.4% | 33.8% |
| Kaynes | 6,373 | 952 | 813 | 13.9% | 21.3% | 54.5% | 9.6% | 9.6% | 3.7% | 4.0% | 6.3% | 5.3% |
| Syrma | 11,341 | 737 | 452 | 52.6% | 40.7% | 33.3% | 2.4% | 4.0% | -9.8% | -16.9% | -11.2% | -18.6% |
| Avalon | 2,168 | 172 | 71 | -16.3% | -28.1% | -42.2% | -22.1% | -15.2% | -18.9% | -7.7% | -30.4% | -16.4% |
| Cyient DLM | 3,618 | 380 | 227 | 8.7% | 22.3% | 4.3% | -2.1% | -2.0% | 5.1% | 10.9% | 7.2% | 12.3% |
| IKIO | 948 | 170 | 95 | -20.0% | -35.8% | -45.6% | | | No Change | | | |
| Elin | 2,778 | 124 | 35 | 1.8% | 22.8% | -25.9% | | | No Change | | | |

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 1: 4QFY24 EBITDA margin profile



4QFY24 results highlights and commentary

Dixon Technologies

- Dixon Technologies achieved a significant milestone by producing 15bn smartphones and 38bn feature phones. Further growth is likely in Motorola smartphones via export orders. It expects a monthly output of 300,000 units of Xiaomi smartphones, starting from May 2024F. The company has started making display modules through its technology partner while the manufacture of precision components and mechanicals is also underway. Production of Airtel's 5G fixed wireless devices has begun, with the mass production scheduled in Jun/Jul 2024F. It also inked a deal with Nokia for 5G fixed wireless devices. Manufacturing partnership with Samsung for the Tizen operating system is on track for rollout. Dixon Technologies has set up a new campus for PCB assembly in Chennai. The company is looking at the opportunity in the PCB assembly EMS space and expects a turnover from next year.
- Outlook:** Dixon Technologies posted healthy FY24 results, with revenue & PAT growth of 45% and 47%, respectively. Its business model is highly scalable and profitable, with high fungibility in its products line. The company has captured a large market share across categories in the consumer electronics outsourcing space, much above its peers. The technological upgradation in 5G infrastructure is poised to open new possibilities for electronic devices, especially in the mobility & communication segments. For FY25F/26F, we have increased our revenue estimates by 16%/21% and PAT estimates by 3%/9%, respectively, factoring in higher revenue in the mobile phone segment with a lower margin. We retain our ADD rating on the stock with a higher target price of Rs9,010 (Rs7,000 earlier), valuing it at 65x (55x earlier) FY26F EPS, in line with average P/E.

Cyient DLM

- Cyient DLM's revenue is expected to continue its strong export-driven growth, with exports accounting for 66% of revenue in FY24. This trend is likely to aid margin growth as export orders typically have higher margins than domestic orders. Additionally, the company aims to improve its working capital requirements from 105 days in FY24 to around 90 days in FY25F, which was already visible in the 4Q results. Furthermore, Europe's increased defence spending due to the Russia-Ukraine war and North Atlantic Treaty Organization or NATO's 2% GDP defence spending target could be a medium-term trigger for growth, particularly for Cyient DLM's clients Thales and Rafale,

who are major manufacturers of air defence systems. This could lead to a significant order inflow for Cyient DLM, resulting in order book growth.

- **Outlook:** Management expects a 30% revenue CAGR over a three-year period. It expects a 25% RoCE in the next five years. The company is looking to address the defence offset opportunity due to the recent geopolitical challenges. Supply chain issues have stabilized over the last 12-15 months. We remain bullish on Cyient DLM's long-term prospects. Its exposure to the aerospace and defence sector, which is in a multi-year upcycle, will aid its order-book growth. We have an ADD rating and value Cyient DLM at 45x FY26F EPS to arrive at a target price of Rs1,049.

Syrma SGS Technology

- Syрма SGS Technology witnessed an increase in its net working capital or NWC days from 88 to 95 in FY24, primarily due to the high inventory level, leading to increased debt and higher interest costs, thereby dampening PAT growth. This indicates the focus on revenue growth over RoCE, potentially leading to subdued performance in the medium term, which could trigger a derating of the stock. Additionally, despite a marginal improvement in the EBITDA margin, the significant decline in gross margin suggests a potential price war among competitors in the EMS space, where differentiation primarily lies in pricing. Furthermore, the lack of barriers to entry in Syрма SGS Technology's assembly of bare PCB boards exposes it to risks of Chinese competitors engaging in price dumping, given their cost advantages due to a superior electronics ecosystem, posing a perpetual threat to the company's competitiveness.
- **Outlook:** The company expects ~40% revenue growth and ~7% EBITDA margin in FY25F. Exports to grow by 30% YoY. We believe there is a fundamental flaw with Syрма SGS Technology's business model as it tries to imitate both Dixon Technologies and Kaynes Technology. Manufacturing at scale is more important for the consumer segment whereas quality and precision matters more for the automotive and industrial segments. We maintain our revenue estimates but lower EBITDA/PAT by 10%/11% for FY25F and 17%/19%, respectively, for FY26F. We have an ADD rating and value the stock at 28x (from 37x) FY26F EPS to arrive at a lower target price of Rs437 (Rs660 earlier).

Kaynes Technology

- Syрма is nearing government approval for its OSAT business. Kaynes Technology is concentrating on advancing plastic and metal enclosures, moulds, tools, and textures, with notable progress in high-performance computing server manufacturing, aerospace, outer space, and medical electronics, securing contracts for both domestic and export markets. Additionally, in the industrial and EV sectors, Kaynes Technology has secured a significant contract with a smart meter company, diversifying its business portfolio. In railway electronics, alongside electronic interlocking projects, Kaynes Technology is involved in TCAS. Moreover, the acquisition of Digicon Electronics in the US aims to bolster its presence there, with a strategy emphasizing proximity to clients for prototyping and new product development while leveraging cost efficiency through production in India.
- **Outlook:** Management gave revenue growth guidance of 50-60% for FY25F, with the EBITDA margin at ~14.5-15%. NWC days are expected to decline to 70-72 days by the end of FY25F. The business model of Kaynes Technology has shifted from low-volume, high-mix in the automotive space to high-volume, low-mix in the industrial and EV segments. Currently, the share of high-volume products is ~60%. Eventually, Kaynes Technology aims to have a 50% share in high-volume products. The order book remains healthy at Rs41bn (2.3x FY24 revenue) while the EBITDA margin is likely to be ~14.5%. For FY25F/26F, we raise revenue estimates by ~10% each and PAT by ~6%/5%, factoring in higher order inflow at a lower margin. We retain HOLD rating on

Kaynes Technology with a higher target price of Rs3,286, (Rs3,120 earlier), valuing it at 55x FY26F EPS.

Amber Enterprises

- Amber Enterprises or AEL has diversified its product portfolio and strengthened its market position. The decline in room AC contribution from 72% in FY18 to 44% in FY24 showcases the company's adaptability to changing market dynamics. AEL secured a PLI grant for AC component manufacturing and initiated a JV with Resojet to produce fully automatic washing machines. The company is set to commence mass production from 2QFY25F, aiming to scale up to 125,000 units in the coming years. Furthermore, AEL's electronics division has evolved significantly, expanding into various sectors like aerospace, defence, and electric vehicle components, bolstered by the acquisition of a 60% stake in Ascent Circuits. Expansion plans include capacity enhancement at greenfield and brownfield facilities, focusing on energy-efficient ACs, railway components, and automobile parts. Strategic alliances with Titagarh and Sidwal have further fortified AEL's position, while government initiatives like anti-dumping duties on imported PCBs support domestic manufacturing growth.
- **Outlook:** AC brands, including Voltas, Blue Star and Lloyd, are increasing their insourcing capacity, a key negative for outsourcing companies like AEL, which is looking to diversify its product portfolio due to the structural shift in the manufacturing space with a lot of companies shifting to in-house manufacturing. For FY25F/26F, we cut our revenue estimates by 7% each to factor in the muted growth in the RAC business but increase PAT estimates by 5%/10%, respectively, due to higher margin in the mobility and electronics segments. We retain HOLD rating on AEL with a higher target price of Rs4,200 (Rs3,810 earlier), valuing it at 35x FY26F EPS.

Avalon Technologies

- Avalon Technologies' strategic focus entails capitalizing on India's manufacturing capabilities and seizing opportunities in the US market through a hybrid manufacturing model and emphasizing on high-growth sectors like clean energy and lucrative segments such as aerospace and defence. Despite challenging economic conditions in the US leading to a Rs300m loss in FY24, Avalon remains committed to improving its US operations, aiming at a recovery from FY26F. With 77% of the revenue coming from domestic manufacturing, it plans to optimize production shift to India and streamline costs at its US operations.
- **Outlook:** Despite lower sales in FY24, management gave guidance of a 14-16% revenue growth in FY25F. We expect Avalon Technologies to continue its underperformance till a strong recovery in the US market, which has been delayed further. On the positive side, the order book and long-term contracts have increased by 26% YoY to Rs13.7bn, the execution of which will take 12-14 months. Avalon Technologies is continuously expanding its technological expertise in manufacturing for diverse industries and integrating its services to serve multiple verticals, with high-mix, flexible-volume manufacturing. For FY25F/26F, we have cut our revenue estimates by 22%/15% and PAT estimates by 30%/16%, respectively, factoring in weak performance and slowdown in the US export business. We downgraded our rating on Avalon Technologies to HOLD (from ADD) with a lower target price of Rs510 (Rs610 earlier), valuing the stock at 35x FY26F EPS.

PG Electroplast

- PG Electroplast's EBITDA margin expansion of 167bp in 4QFY24 was aided by PLI and other incentives worth Rs200m. Excluding this, margins were flat. PGEL's joint venture with Jaina, Goodworth Ventures, was chosen for IT PLI 2.0, yet by the end of 4QFY24, no manufacturing partner had been selected. With market leaders in the laptop sector like HP, Dell, Lenovo, and Acer either self-manufacturing or partnering with Dixon Technologies, finding a suitable

OEM partner for PGEL becomes challenging, potentially hindering its ability to meet the steep sales targets required for IT PLI incentives. RAC sales are expected to drive PGEL's growth in FY25F, while its coolers and washing machines are slow to ramp up. With competition intensifying, particularly in washing machines with Dixon Technologies and Amber Enterprises' entry, PGEL's reliance on the RAC sector for growth poses a risk, especially considering the anticipated slowdown post FY25F, potentially resulting in the company missing its growth targets.

- **Outlook:** Going ahead, PLI incentives will be in the range of Rs0.55-0.60bn for FY25F and FY26F. We revised our revenue/ EBITDA/PAT estimates for FY25F and FY26F by -3%/ 38%/ 57% and -8%/25%/34%, respectively, to account for the PLI incentives of Rs650m in FY25F and FY26F. However, as these are seasonal incentives, we have our REDUCE rating and value PGEL at a lower multiple of 22x (25x earlier) to arrive at a new target price of Rs1,755.

IKIO Lighting

- We believe IKIO Lighting's 24%+ EBITDA margin is not sustainable in the long run, and with the lighting industry facing headwinds the company's 4QFY24 EBITDA margin of 17% could decline further in the coming quarters. Margin decline, coupled with rising net working capital days, is a recipe for disaster and hence, return ratios are also expected to come down in FY25F. The RV business in USA, where IKIO Lighting has Forrest River as its client, is also not showing revival post Covid-19 pandemic-led highs due to pent-up demand and hence, exports ramp-up also looks unlikely in the medium term.
- **Outlook:** IKIO Lighting has strong potential in RV lighting, with total market potential for the company in this segment at Rs5,000m, thus implying a 14% market share. However, YoY RV sales in the US are down significantly due to the prevailing macroeconomic slowdown. Hence, we do not expect much growth in this segment. We have a REDUCE rating on the stock with a target price of Rs260, valuing it at 19x EV/EBITDA multiple and we feel there are not many growth triggers in the medium term.

Elin Electronics

- Elin Electronics reported EBITDA margin expansion of 116 bp YoY. While the lighting industry is facing headwinds, the company has not shown any reduction in gross margin, which shows a level of pricing power with end-consumers. The current portfolio mainly consists of small appliances ranging from lighting solutions, shavers, trimmers and ceiling fans. However, the company is transitioning from the small appliances business to medium appliances like oil-filled radiators, which is an import substitution opportunity. Secondly, the company is also moving away from the exclusivity contract with Signify Lighting, which will also allow it to cater to other clients, thus diversifying the client base. The revoking of this exclusivity contract has not resulted in any opportunity loss for Elin Electronics.
- **Outlook:** Elin Electronics will likely post 16% and 19% YoY topline growth in FY25F and FY26F, respectively. We also believe the company will improve its margins from ~4% in FY24 to 6% in FY25F and to 7.3% in FY26F. As the topline growth starts, operating leverage will come into play, which will aid the margins. Capacity utilization is currently at 60%, and the company has the capacity to generate a potential revenue of Rs18,000m. We have an ADD rating on the stock with a target price of Rs198, valuing the stock at 15x FY26F EPS.

Peer comparison and valuation

Figure 2: Revenue comparison

| Revenue (Rs m) | FY20 | FY21 | FY22 | FY23 | FY24 | FY25F | FY26F |
|--------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Dixon | 44,001 | 64,482 | 1,06,971 | 1,21,920 | 1,76,911 | 2,45,031 | 3,14,317 |
| Amber | 39,628 | 30,305 | 42,064 | 69,271 | 67,292 | 79,478 | 94,496 |
| PGEL | 6,394 | 7,032 | 10,977 | 21,599 | 27,465 | 32,751 | 37,127 |
| Kaynes | 3,614 | 4,164 | 7,014 | 11,261 | 18,046 | 27,396 | 38,555 |
| Syrma | 8,657 | 8,874 | 10,197 | 20,484 | 31,538 | 45,032 | 63,025 |
| Avalon | 6,418 | 6,902 | 8,407 | 9,447 | 8,672 | 10,102 | 13,507 |
| Cyient DLM | 4,571 | 6,280 | 7,205 | 8,320 | 11,918 | 16,428 | 21,458 |
| IKIO | 2,202 | 2,134 | 3,318 | 3,588 | 4,379 | 5,163 | 6,376 |
| Elin | 7,856 | 8,624 | 10,938 | 10,754 | 10,418 | 12,057 | 14,338 |
| Total | 1,15,485 | 1,30,173 | 1,96,154 | 2,65,891 | 3,46,221 | 4,61,381 | 5,88,862 |
| Revenue Growth (%) | FY20 | FY21 | FY22 | FY23 | FY24 | FY25F | FY26F |
| Dixon | | 46.5% | 65.9% | 14.0% | 45.1% | 38.5% | 28.3% |
| Amber | | -23.5% | 38.8% | 64.7% | -2.9% | 18.1% | 18.9% |
| PGEL | | 10.0% | 56.1% | 96.8% | 27.2% | 19.2% | 13.4% |
| Kaynes | | 15.2% | 68.5% | 60.5% | 60.3% | 51.8% | 40.7% |
| Syrma | | 2.5% | 14.9% | 100.9% | 54.0% | 42.8% | 40.0% |
| Avalon | | 7.5% | 21.8% | 12.4% | -8.2% | 16.5% | 33.7% |
| Cyient DLM | | 37.4% | 14.7% | 15.5% | 43.2% | 37.8% | 30.6% |
| IKIO | | -3.1% | 55.5% | 8.1% | 22.0% | 17.9% | 23.5% |
| Elin | | 9.8% | 26.8% | -1.7% | -3.1% | 15.7% | 18.9% |

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 3: EBITDA comparison

| EBITDA (Rs m) | FY20 | FY21 | FY22 | FY23 | FY24 | FY25F | FY26F |
|-------------------|-------|-------|-------|-------|-------|--------|--------|
| Dixon | 1,699 | 3,029 | 2,687 | 5,183 | 6,978 | 10,305 | 13,607 |
| Amber | 3,093 | 2,203 | 2,754 | 4,179 | 4,918 | 6,629 | 8,262 |
| PGEL | 399 | 498 | 751 | 1,760 | 2,618 | 3,376 | 3,572 |
| Kaynes | 345 | 367 | 889 | 1,683 | 2,542 | 3,924 | 5,586 |
| Syrma | 1,366 | 999 | 944 | 1,878 | 2,095 | 3,154 | 4,149 |
| Avalon | 644 | 659 | 975 | 1,128 | 626 | 1,054 | 1,581 |
| Cyient DLM | 137 | 459 | 840 | 878 | 1,109 | 1,797 | 2,600 |
| IKIO | 373 | 478 | 773 | 775 | 926 | 959 | 1,154 |
| Elin | 555 | 665 | 790 | 651 | 406 | 723 | 1,047 |
| EBITDA Margin (%) | FY20 | FY21 | FY22 | FY23 | FY24 | FY25F | FY26F |
| Dixon | 3.9% | 4.7% | 2.5% | 4.3% | 3.9% | 4.2% | 4.3% |
| Amber | 7.8% | 7.3% | 6.5% | 6.0% | 7.3% | 8.3% | 8.7% |
| PGEL | 6.2% | 7.1% | 6.8% | 8.2% | 9.5% | 10.3% | 9.6% |
| Kaynes | 9.5% | 8.8% | 12.7% | 14.9% | 14.1% | 14.3% | 14.5% |
| Syrma | 15.8% | 11.3% | 9.3% | 9.2% | 6.6% | 7.0% | 6.6% |
| Avalon | 10.0% | 9.5% | 11.6% | 11.9% | 7.2% | 10.4% | 11.7% |
| Cyient DLM | 3.0% | 7.3% | 11.7% | 10.6% | 9.3% | 10.9% | 12.1% |
| IKIO | 16.9% | 22.4% | 23.3% | 21.6% | 21.2% | 18.6% | 18.1% |
| Elin | 7.1% | 7.7% | 7.2% | 6.1% | 3.9% | 6.0% | 7.3% |

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 4: PAT comparison

| PAT | FY20 | FY21 | FY22 | FY23 | FY24 | FY25F | FY26F |
|----------------|-------|---------|--------|--------|--------|--------|-------|
| Dixon | 1,205 | 1,598 | 1,903 | 2,547 | 3,781 | 6,003 | 8,289 |
| Amber | 1,584 | 816 | 1,092 | 1,572 | 1,373 | 2,859 | 4,042 |
| PGEL | 22 | 121 | 385 | 775 | 1,370 | 1,897 | 2,076 |
| Kaynes | 26 | 51 | 369 | 952 | 1,834 | 2,741 | 3,819 |
| Syrma | 914 | 652 | 567 | 1,231 | 1,257 | 1,943 | 2,760 |
| Avalon | 123 | 231 | 475 | 525 | 280 | 578 | 952 |
| Cyient DLM | -67 | 118 | 398 | 317 | 611 | 1,207 | 1,867 |
| IKIO | 214 | 288 | 505 | 500 | 605 | 560 | 700 |
| Elin | 275 | 349 | 391 | 268 | 140 | 413 | 657 |
| PAT Growth (%) | FY20 | FY21 | FY22 | FY23 | FY24 | FY25F | FY26F |
| Dixon | | 32.6% | 19.1% | 33.8% | 48.4% | 58.8% | 38.1% |
| Amber | | -48.5% | 33.8% | 44.0% | -12.7% | 108.2% | 41.4% |
| PGEL | | 450.5% | 217.5% | 101.2% | 76.8% | 38.4% | 9.4% |
| Kaynes | | 99.6% | 617.3% | 158.3% | 92.7% | 49.4% | 39.3% |
| Syrma | | -28.7% | -13.1% | 117.3% | 2.1% | 54.6% | 42.1% |
| Avalon | | 87.3% | 105.7% | 10.7% | -46.7% | 106.6% | 64.6% |
| Cyient DLM | | -275.8% | 237.2% | -20.3% | 92.5% | 97.6% | 54.7% |
| IKIO | | 34.6% | 75.4% | -1.0% | 20.9% | -7.4% | 25.0% |
| Elin | | 26.8% | 12.3% | -31.5% | -47.9% | 196.0% | 59.1% |

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 5: RoE and RoCE comparison

| RoCE | FY20 | FY21 | FY22 | FY23 | FY24 | FY25F | FY26F |
|------------|--------|-------|-------|-------|-------|-------|-------|
| Dixon | 28.0% | 24.8% | 19.2% | 22.9% | 23.7% | 27.3% | 27.2% |
| Amber | 16.4% | 7.3% | 7.0% | 9.3% | 9.1% | 13.3% | 16.3% |
| PGEL | 6.8% | 8.1% | 9.2% | 15.8% | 16.7% | 17.0% | 16.4% |
| Kaynes | 16.9% | 14.1% | 29.1% | 14.9% | 5.0% | 7.2% | 9.3% |
| Syrma | 38.0% | 38.8% | 15.6% | 14.5% | 9.6% | 12.4% | 15.8% |
| Avalon | 21.4% | 17.7% | 23.9% | 16.6% | 6.6% | 11.9% | 16.6% |
| Cyient DLM | 4% | 13% | 20% | 15% | 10% | 16% | 21% |
| IKIO | 71.7% | 36.7% | 39.3% | 29.3% | 18.2% | 11.7% | 12.1% |
| Elin | | 11.9% | 12.3% | 7.2% | 2.4% | 7.8% | 11.3% |
| ROE | FY20 | FY21 | FY22 | FY23 | FY24 | FY25F | FY26F |
| Dixon | 22.3% | 21.7% | 19.1% | 19.8% | 22.3% | 26.4% | 27.0% |
| Amber | 15.0% | 6.0% | 6.5% | 8.6% | 7.0% | 13.0% | 15.8% |
| PGEL | 2.7% | 6.7% | 14.7% | 21.9% | 19.1% | 16.7% | 15.6% |
| Kaynes | 2.5% | 4.6% | 21.6% | 16.4% | 6.7% | 5.9% | 7.7% |
| Syrma | 44.7% | 38.2% | 13.1% | 11.6% | 7.8% | 11.0% | 13.7% |
| Avalon | 26.8% | 42.8% | 63.8% | 16.8% | 5.2% | 10.0% | 14.6% |
| Cyient DLM | -26% | 31% | 52% | 16% | 7% | 12% | 15% |
| IKIO | 119.3% | 58.3% | 58.8% | 39.9% | 17.4% | 9.8% | 11.3% |
| Elin | | 14.2% | 13.8% | 6.7% | 2.8% | 7.9% | 11.6% |

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 6: P/E comparison

| P/E (x) | FY20 | FY21 | FY22 | FY23 | FY24 | FY25F | FY26F |
|------------|---------|---------|-------|-------|-------|-------|-------|
| Dixon | 488.6 | 368.4 | 309.3 | 231.1 | 155.7 | 98.1 | 71.0 |
| Amber | 79.2 | 153.7 | 114.9 | 79.8 | 91.4 | 43.9 | 31.0 |
| PGEL | 3,228.7 | 586.5 | 184.7 | 91.8 | 51.9 | 37.5 | 34.3 |
| Kaynes | 8,731.5 | 4,375.4 | 610.0 | 236.2 | 122.6 | 82.0 | 58.9 |
| Syrma | 95.9 | 134.4 | 154.6 | 71.2 | 69.7 | 45.1 | 31.7 |
| Avalon | 260.9 | 139.3 | 67.8 | 61.2 | 114.9 | 55.6 | 33.8 |
| Cyient DLM | -785.4 | 446.8 | 132.5 | 166.2 | 86.3 | 43.7 | 28.2 |
| IKIO | 95.0 | 70.6 | 40.3 | 40.7 | 33.6 | 36.3 | 29.0 |
| Elin | 29.4 | 23.2 | 20.6 | 30.1 | 57.8 | 19.5 | 12.3 |

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 7: EV/EBITDA multiple trend

| EV/EBITDA (x) | FY20 | FY21 | FY22 | FY23 | FY24 | FY25F | FY26F |
|---------------|-------|-------|-------|-------|------|-------|-------|
| Dixon | 346.4 | 194.6 | 220.1 | 113.5 | 84.5 | 57.0 | 43.1 |
| Amber | 41.4 | 57.4 | 47.2 | 31.9 | 27.0 | 19.8 | 15.8 |
| PGEL | 181.5 | 145.2 | 98.1 | 42.5 | 28.1 | 21.7 | 20.5 |
| Kaynes | 655.3 | 616.4 | 254.8 | 131.5 | 83.7 | 54.9 | 39.1 |
| Syrma | 64.5 | 87.9 | 94.5 | 48.2 | 44.2 | 28.5 | 21.7 |
| Avalon | 53.4 | 52.8 | 35.9 | 27.5 | 52.3 | 31.1 | 20.8 |
| Cyient DLM | 398.2 | 119.1 | 64.8 | 61.7 | 44.6 | 27.8 | 18.8 |
| IKIO | 55.5 | 43.8 | 27.5 | 27.7 | 20.4 | 21.7 | 17.7 |
| Elin | 15.6 | 13.8 | 11.5 | 12.1 | 19.3 | 10.5 | 6.8 |

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 8: Net debt comparison

| Net Debt | FY20 | FY21 | FY22 | FY23 | FY24 | FY25F | FY26F |
|------------|-------|-------|-------|--------|---------|--------|--------|
| Dixon | -135 | 872 | 2,757 | -466 | 688 | -1,205 | -2,610 |
| Amber | 2,472 | 944 | 4,692 | 7,843 | 7,419 | 6,104 | 5,042 |
| PGEL | 1,276 | 1,109 | 2,520 | 3,681 | 2,416 | 2,150 | 2,051 |
| Kaynes | 1,101 | 1,109 | 1,531 | -3,501 | -12,195 | -9,273 | -6,331 |
| Syrma | 422 | 185 | 1,573 | 2,924 | 4,907 | 2,310 | 2,375 |
| Avalon | 2,219 | 2,618 | 2,839 | -1,160 | 576 | 562 | 719 |
| Cyient DLM | 1,952 | 1,996 | 1,714 | 1,469 | -3,228 | -2,803 | -3,786 |
| IKIO | 360 | 600 | 938 | 1,124 | -1,458 | 481 | 54 |
| Elin | 596 | 1,084 | 974 | -218 | -222 | -450 | -914 |

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 9: Working capital days comparison

| NWC Days | FY20 | FY21 | FY22 | FY23 | FY24 | FY25F | FY26F |
|------------|------|------|------|------|------|-------|-------|
| Dixon | -4 | -5 | 7 | 7 | 7 | -2 | 6 |
| Amber | 17 | 24 | 11 | 7 | -5 | -22 | -20 |
| PGEL | 61 | 80 | 90 | 66 | 86 | 56 | 57 |
| Kaynes | 169 | 160 | 126 | 146 | 125 | 104 | 105 |
| Syrma | 21 | 29 | 106 | 88 | 95 | 62 | 58 |
| Avalon | 67 | 96 | 113 | 111 | 150 | 153 | 151 |
| Cyient DLM | 36 | 45 | 56 | 41 | 113 | 74 | 64 |
| IKIO | 57 | 115 | 157 | 172 | 176 | 125 | 119 |
| Elin | 50 | 66 | 68 | 69 | 70 | 63 | 61 |

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 10: Price/book value per share comparison

| P/BV (x) | FY20 | FY21 | FY22 | FY23 | FY24 | FY25F | FY26F |
|------------|-------|-------|-------|------|------|-------|-------|
| Dixon | 108.8 | 79.8 | 59.1 | 45.8 | 34.7 | 25.9 | 19.2 |
| Amber | 10.8 | 7.6 | 7.1 | 6.4 | 5.9 | 5.2 | 4.5 |
| PGEL | 45.4 | 41.2 | 24.4 | 19.1 | 7.0 | 5.9 | 5.0 |
| Kaynes | 217.8 | 161.1 | 110.4 | 23.4 | 9.0 | 8.1 | 7.2 |
| Syrma | 86.1 | 36.3 | 15.0 | 5.7 | 5.2 | 4.7 | 4.1 |
| Avalon | 933.2 | 113.4 | 36.3 | 6.0 | 5.9 | 5.3 | 4.6 |
| Cyient DLM | 205.1 | 140.0 | 68.4 | 26.6 | 5.8 | 5.1 | 4.3 |
| IKIO | 56.6 | 32.4 | 18.7 | 14.3 | 3.7 | 3.4 | 3.2 |
| Elin | 3.5 | 3.1 | 2.7 | 1.6 | 1.6 | 1.5 | 1.4 |

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 11: EPS trend

| EPS | FY20 | FY21 | FY22 | FY23 | FY24 | FY25F | FY26F |
|------------|------|------|------|------|------|-------|-------|
| Dixon | 20.2 | 26.8 | 32.0 | 42.8 | 63.5 | 100.8 | 139.2 |
| Amber | 47.0 | 24.2 | 32.4 | 46.7 | 40.7 | 84.9 | 120.0 |
| PGEL | 0.8 | 4.7 | 14.8 | 29.8 | 52.6 | 72.9 | 79.8 |
| Kaynes | 0.4 | 0.8 | 5.8 | 14.9 | 28.7 | 42.9 | 59.7 |
| Syrma | 5.2 | 3.7 | 3.2 | 7.0 | 7.1 | 11.0 | 15.6 |
| Avalon | 1.9 | 3.5 | 7.2 | 8.0 | 4.3 | 8.8 | 14.5 |
| Cyient DLM | -0.8 | 1.5 | 5.0 | 4.0 | 7.7 | 15.2 | 23.5 |
| IKIO | 2.8 | 3.7 | 6.5 | 6.5 | 7.8 | 7.2 | 9.1 |
| Elin | 5.5 | 7.0 | 7.9 | 5.4 | 2.8 | 8.3 | 13.2 |

SOURCE: INCRED RESEARCH, COMPANY REPORTS

DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd. (formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000011024. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which are believed to be accurate and complete and obtained through reliable public or other non-confidential sources at the time made. (Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short term views etc.) that are inconsistent with and reach different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report

| | Analyst/ Relative | Entity/ Associates |
|---|----------------------|-----------------------|
| any financial interests in the company covered in this report (subject company) and nature of such financial interest | NO | NO |
| actual/beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the research report or date of the public appearance; | NO | NO |
| any other material conflict of interest at the time of publication of the research report or at the time of public appearance | NO | NO |
| received any compensation from the subject company in the past twelve months for investment banking or merchant banking or brokerage services or investment advisory or depository or distribution from the subject company in the last twelve months for products/services other than investment banking or merchant banking or broker- age services or investment advisory or depository or distribution from the subject company in the last twelve months | NO | NO |
| managed or co-managed public offering of securities for the subject company in the last twelve months | NO | NO |
| received any compensation or other benefits from the subject company or third party in connection with the research report | NO | NO |
| served as an officer, director or employee of the subject company | NO | NO |
| been engaged in market making activity for the subject company | NO | NO |

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in this report and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.